Do complex cytogenetics have any therapeutic or prognostic relevance in CLL?

When do you test NGS for resistance mutations (such as PLCG2, BTK) in patients with CLL?

• I test for PLCG2 and BTK mutations as part of the initial diagnostic workup for all CLL patients
• I test for PLCG2 and BTK mutations for any patient relapsing/progressing on first covalent BTKi, only if planning to move to a second non-covalent BTKi (such as pirtobrutinib)
• I test for PLCG2 and BTK mutations for any patient relapsing/progressing on first covalent BTKi, regardless of next planned therapy
• I selectively test for PLCG2 mutations only, based on specific clinical indications (please specify)
• I selectively test for BTK mutations only, based on specific clinical indications (please specify)
• I rarely or never test for PLCG2 or BTK mutations in CLL patients
• Other